Analyzing the tumor to predict cancer treatment response

Our diagnostics use AI to interpret solid tumors, so physicians and patients can make evidence-based decisions about cancer treatments

See our approach

Our vision for more informed patients and physicians

Our mission is to remove the uncertainty from cancer treatment decisions, so physicians and patients don’t have to make educated guesses about therapy selection

Our AI diagnostics deliver unparalleled insights into the tumor microenvironment and its downstream effects

Provide clear and actionable reports indicating the likelihood of therapeutic response

Patients and their loved ones can make more confident decisions based on unique evidence

Physicians are empowered to make informed treatment decisions, and improve the likelihood of success

Vesta is the only bladder cancer diagnostic that predicts treatment response to BCG using routine histology

See the evidence


Partnering with pharma to accelerate early research

We work with leading pharmaceutical companies, deploying our AI algorithms to advance R&D programs

Work with us

Discovering biomarkers that predict response to therapies

Deploying diagnostics for biomarkers associated with therapy response

Automating screening for molecular biomarkers to increase enrollment, lower costs


Valar Labs was founded to remove uncertainty from treatment decisions

Today, therapy selection is filled with uncertainty for oncologists and patients. Valar Labs exists to help them make more informed treatment decisions when it matters most.

About Valar Labs


Announcing Our $22 Million Series A to Accelerate AI in Precision Oncology

Co-led by DCVC and a16z, this funding will support the advancement of Vesta, world's first AI test to predict treatment response in bladder cancer, and catalyze expansion in other cancers.

View Article
View Article